2018 Community Diagnosis Patients 
Common Sense Family Doctor
DECEMBER 14, 2024
Concerns about overdiagnosis of clinically insignificant prostate cancer through prostate specific antigen (PSA) screening motivated the 2018 American Academy of Family Physicians’ (AAFP) recommendation against routine screening for prostate cancer. Explaining the AAFP’s position, Drs. Watchful waiting refers to clinical observation only.
FDA Law Blog
OCTOBER 30, 2022
This draft guidance proposes updates to FDA’s Breakthrough Devices Program, which is outlined in a separate December 2018 guidance document. FDA intends to incorporate these updates into the December 2018 Breakthrough Devices Program guidance after considering public comment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PEMBlog
SEPTEMBER 24, 2024
PEMPix is the American Academy of Pediatrics Section on Emergency Medicine’s annual visual diagnosis competition. This case was submitted by Dr. At that point, he was referred to pulmonology who started the patient on albuterol, manual chest physiotherapy, and a steroid inhaler with a plan for a fourth chest x-ray four weeks later.
FDA Law Blog
FEBRUARY 27, 2023
The Ryan Haight Act did not limit the ability to prescribe controlled substance medications by telemedicine so long as the patient and prescriber had a least one in-person visit. a prescriber that engages in telemedicine with the patient), including a review of PDMP data for the past year. 21 U.S.C. § 802(54)(D)(i).
GeriPal
JUNE 8, 2023
When I’m on palliative care consults and attending in our hospice unit we have to counsel patients about deprescribing and de-intensifying diabetes medications. Our last podcast was with Laura Petrillo in 2018 – 5 years ago seems ancient history – though many of the points still apply today (e.g. Goldilocks zone).
FDA Law Blog
JANUARY 6, 2022
Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. However, Graves’s clients were physicians/physician offices — not individual patients in need of lab services.
FDA Law Blog
JANUARY 6, 2022
Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. However, Graves’s clients were physicians/physician offices — not individual patients in need of lab services.
Expert insights. Personalized for you.
52 
Let's personalize your content